Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan.
J Nutr Biochem. 2013 May;24(5):796-802. doi: 10.1016/j.jnutbio.2012.04.013. Epub 2012 Aug 13.
Diabetic kidney disease has been associated with the presence of lipid deposits. We assumed that curcumin, a polyphenol, would attenuate the tissue dyslipidemic condition through activation of 5' adenosine monophosphate (AMP)-activated protein kinase (AMPK) phosphorylation and suppression of sterol regulatory element-binding protein (SREBP)-1c in the kidney and would prevent renal progression in experimental type 1 diabetic rats. Diabetes was induced with streptozotocin (STZ) (55 mg/kg) by intraperitoneal injection in male Sprague-Dawley rats. Three weeks after STZ injection, rats were divided into three groups, namely, control, diabetic and diabetic treated with curcumin (100 mg/kg/day) by gavage for 8 weeks. We found that curcumin decreased plasma triglyceride and the amount of renal triglyceride significantly. Furthermore, treatment of diabetic rats with curcumin increased the phosphorylation of AMPK and prevented the increased renal expression of SREBP-1c and, as a result, decreased the expression of acetyl CoA carboxylase and fatty acid synthase as well as adipose differentiation-related protein, a marker of cytoplasmic droplets. We also demonstrate that curcumin significantly suppressed the increased expression of transforming growth factor β, vascular endothelial growth factor and extracellular matrix proteins such as type IV collagen and fibronectin. In addition, curcumin treatment increased nephrin expression to near-normal levels in diabetic rats. These results demonstrated that curcumin protects against the development of diabetic nephropathy through the AMPK-SREBP pathway and the reduction of renal triglyceride accumulation which could be a possible mechanism by which curcumin preserves renal function in diabetes.
糖尿病肾病与脂质沉积的存在有关。我们假设姜黄素,一种多酚,通过激活 5' 腺苷单磷酸(AMP)激活蛋白激酶(AMPK)磷酸化和抑制固醇调节元件结合蛋白(SREBP)-1c 在肾脏中,会减轻组织血脂异常状况,并防止实验性 1 型糖尿病大鼠的肾脏进展。通过腹腔注射链脲佐菌素(STZ)(55mg/kg)在雄性 Sprague-Dawley 大鼠中诱导糖尿病。在 STZ 注射后 3 周,将大鼠分为三组,即对照组、糖尿病组和糖尿病用姜黄素(100mg/kg/天)灌胃 8 周的治疗组。我们发现姜黄素可显著降低血浆甘油三酯和肾脏甘油三酯含量。此外,用姜黄素治疗糖尿病大鼠可增加 AMPK 的磷酸化,并防止 SREBP-1c 在肾脏中的表达增加,从而减少乙酰 CoA 羧化酶和脂肪酸合酶的表达以及脂肪分化相关蛋白(细胞质空泡的标志物)。我们还证明姜黄素可显著抑制转化生长因子β、血管内皮生长因子和细胞外基质蛋白(如 IV 型胶原和纤维连接蛋白)表达的增加。此外,姜黄素治疗可使糖尿病大鼠的足细胞蛋白 Nephrin 的表达接近正常水平。这些结果表明,姜黄素通过 AMPK-SREBP 途径和减少肾脏甘油三酯积累来保护糖尿病肾病的发生,这可能是姜黄素在糖尿病中保护肾功能的一种机制。